Androgen Deprivation Therapy News and Research

RSS
Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

New analysis shows correlation between testosterone-lowering therapy for prostate cancer and dementia

New analysis shows correlation between testosterone-lowering therapy for prostate cancer and dementia

Endostatin can decrease proliferation of castration-resistant prostate cancer cells

Endostatin can decrease proliferation of castration-resistant prostate cancer cells

Combination therapy that targets immune-busting cells effective in treating advanced prostate cancer

Combination therapy that targets immune-busting cells effective in treating advanced prostate cancer

ADT for treating advanced prostate cancer not linked to increased risk of Alzheimer disease

ADT for treating advanced prostate cancer not linked to increased risk of Alzheimer disease

Roswell Park researchers identify gene signatures that may help predict fatal prostate cancers

Roswell Park researchers identify gene signatures that may help predict fatal prostate cancers

Common hormone therapy to treat prostate cancer may increase dementia risk in men

Common hormone therapy to treat prostate cancer may increase dementia risk in men

African-American men treated with ADT for prostate cancer suffer from high mortality rates

African-American men treated with ADT for prostate cancer suffer from high mortality rates

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Vanderbilt physicians examine risk factors for cardiovascular disease in prostate cancer survivors

Vanderbilt physicians examine risk factors for cardiovascular disease in prostate cancer survivors

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

New discovery may soon make prostate cancer cells easier to destroy

New discovery may soon make prostate cancer cells easier to destroy

Androgen deprivation therapy elevates Alzheimer’s risk

Androgen deprivation therapy elevates Alzheimer’s risk

Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Prostate cancer patients more likely to receive medical care matched to level of risk

Prostate cancer patients more likely to receive medical care matched to level of risk

Prostate cancer patients can experience cognitive impairment following androgen deprivation therapy

Prostate cancer patients can experience cognitive impairment following androgen deprivation therapy

Prostate cancer patients who receive androgen deprivation therapy may experience cognitive problems

Prostate cancer patients who receive androgen deprivation therapy may experience cognitive problems

Moffitt scientists examine why prostate cancer patients who receive ADT experience hot flashes

Moffitt scientists examine why prostate cancer patients who receive ADT experience hot flashes